SAKK trial [41] | US phase II trial [44] | EORTC 08031 [43] | |
Patients/institutions n | 61/6 | 77/9 | 59/11 |
Induction regimen | Cis-gem ×3 | Cis-pem ×4 | Cis-pem ×3 |
Compliance to induction chemotherapy | 95 | 83 | 93 |
EPP | 45 (74) | 54 (70) | 42 (74) |
Operative mortality | 2.2 | 7 | 6.5 |
pCR rate | 2.2 | 5 | 4.8 |
PORT completed | 36 (59) | 40 (52) | 37 (65) |
OS months | |||
ITT | 19.8 (14.6–24.5) | 16.8 (13.6–23.2) | 18.4 (15.6–32.9) |
PP | 23.0 (16.6–32.9) | 21.9 (16.8–29.1) | 21.5 (17.6–NR) |
PP local relapse | NS | 11 (28) | 6 (16) |
ITT PFS months | 13.5 (10.2–18.8) | 10.1 (8.6–15.0) | 13.9 (10.9–17.2) |
Overall treatment time days median (range) | NS | NS | 193 (162–220) |
Data are presented as %, n (%) or median (95% CI), unless otherwise stated. SAKK: Swiss Group for Clinical Cancer Research; EORTC: European Organisation for Research and Treatment of Cancer; EPP: extrapleural pneumonectomy; pCR: pathologically complete response; PORT: post-operative radiotherapy; OS: overall survival; ITT: intention to treat; PP: per protocol; PFS: progression-free survival; Cis-gem: cisplatin-gemcitabine; Cis-pem: cisplatin-pemetrexed; NR: not reached; NS: not stated.